18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 12, 2010, Pages 2277-2285

  Poisson, Thomas ^a,b   Deandreis, Désirée ^a   Leboulleux, Sophie ^a   Bidault, François ^a   Bonniaud, Guillaume ^a   Baillot, Sylvain ^a   Aupérin, Anne ^a   Al Ghuzlan, Abir ^a   Travagli, Jean Paul ^a   Lumbroso, Jean ^a   Baudin, Eric ^a   Schlumberger, Martin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

18F FDG; Anaplastic thyroid carcinoma; PET CT

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; OXIDRONATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PROGNOSIS; THYROID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 78649777095     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1570-6     Document Type: Article

References (40)

1. FD Gilliland WC Hunt DM Morris CR Key 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991 Cancer 79 564 573 1:STN:280:DyaK2s7otVWqsQ%3D%3D 10.1002/(SICI)1097-0142(19970201)79:3<564:: AID-CNCR20>3.0.CO;2-0 9028369 (Pubitemid 27051783)
2. KB Ain 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches Thyroid 8 715 726 1:STN:280:DyaK1cvgslertA%3D%3D 10.1089/thy.1998.8.715 9737368
3. JL Pasieka 2003 Anaplastic thyroid cancer Curr Opin Oncol 15 78 83 10.1097/00001622-200301000-00012 12490766 (Pubitemid 36135652)
4. JP O'Neill B O'Neill C Condron M Walsh D Bouchier-Hayes 2005 Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease J Laryngol Otol 119 585 591 16102210
5. C Are AR Shaha 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Ann Surg Oncol 13 453 464 10.1245/ASO.2006.05.042 16474910
6. WR Cornett AK Sharma TA Day MS Richardson RS Hoda JA van Heerden, et al. 2007 Anaplastic thyroid carcinoma: an overview Curr Oncol Rep 9 152 158 10.1007/s11912-007-0014-3 17288883 (Pubitemid 46332389)
7. E Kebebew FS Greenspan OH Clark KA Woeber A McMillan 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors Cancer 103 1330 1335 10.1002/cncr.20936 15739211 (Pubitemid 40410726)
8. YS Venkatesh NG Ordonez PN Schultz RC Hickey H Goepfert NA Samaan 1990 Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases Cancer 66 321 330 1:STN:280:DyaK3czhsFGrsQ%3D%3D 10.1002/1097-0142(19900715)66: 2<321::AID-CNCR2820660221>3.0.CO;2-A 1695118 (Pubitemid 20205915)
9. M Schlumberger C Parmentier MJ Delisle JE Couette JP Droz D Sarrazin 1991 Combination therapy for anaplastic giant cell thyroid carcinoma Cancer 67 564 566 1:STN:280:DyaK3M%2FptFyjsA%3D%3D 10.1002/1097-0142(19910201)67:3<564:: AID-CNCR2820670306>3.0.CO;2-E 1985750
10. JG Demeter SA De Jong AM Lawrence E Paloyan 1991 Anaplastic thyroid carcinoma: risk factors and outcome Surgery 110 956 961 1:STN:280: DyaK38%2FotFSjug%3D%3D 1745983 discussion 961-963
11. RK Tan RK Finley 3rd D Driscoll V Bakamjian WL Hicks Jr DP Shedd 1995 Anaplastic carcinoma of the thyroid: a 24-year experience Head Neck 17 41 47 1:STN:280:DyaK2M7ovFCqug%3D%3D 10.1002/hed.2880170109 7883548 discussion 47-48
12. O Nilsson J Lindeberg J Zedenius E Ekman J Tennvall H Blomgren, et al. 1998 Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period World J Surg 22 725 730 1:STN:280: DyaK1c3ntV2rsg%3D%3D 10.1007/s002689900460 9606289 (Pubitemid 28277869)
13. C Passler C Scheuba G Prager K Kaserer JA Flores H Vierhapper, et al. 1999 Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis Langenbecks Arch Surg 384 284 293 1:STN:280:DyaK1MzmsVejtA%3D%3D 10.1007/s004230050205 10437618 (Pubitemid 29309073)
14. N Besic M Auersperg M Us-Krasovec R Golouh S Frkovic-Grazio A Vodnik 2001 Effect of primary treatment on survival in anaplastic thyroid carcinoma Eur J Surg Oncol 27 260 264 1:STN:280:DC%2BD3M3ptVWmtA%3D%3D 10.1053/ejso.2000.1098 11373102 (Pubitemid 32621750)
15. I Sugitani N Kasai Y Fujimoto A Yanagisawa 2001 Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid World J Surg 25 617 622 1:STN:280:DC%2BD3M3ns1Gjtg%3D%3D 10.1007/s002680020166 11369989 (Pubitemid 32441436)
16. PI Haigh PH Ituarte HS Wu PA Treseler MD Posner JM Quivey, et al. 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival Cancer 91 2335 2342 1:STN:280:DC%2BD3MzkvFGrsA%3D%3D 10.1002/1097-0142(20010615)91: 12<2335::AID-CNCR1266>3.0.CO;2-1 11413523 (Pubitemid 32552820)
17. B McIver ID Hay DF Giuffrida CE Dvorak CS Grant GB Thompson, et al. 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution Surgery 130 1028 1034 1:STN:280:DC%2BD3MjgtFehtw%3D%3D 10.1067/msy.2001.118266 11742333 (Pubitemid 34014569)
18. R De Crevoisier E Baudin A Bachelot S Leboulleux JP Travagli B Caillou, et al. 2004 Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy Int J Radiat Oncol Biol Phys 60 1137 1143 15519785
19. V Goutsouliak JH Hay 2005 Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study Clin Oncol (R Coll Radiol) 17 75 78 1:STN:280:DC%2BD2M7ps12ksg%3D%3D
20. N Besic M Hocevar J Zgajnar A Pogacnik S Grazio-Frkovic M Auersperg 2005 Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients Langenbecks Arch Surg 390 203 208 10.1007/s00423-004-0524-5 15599758 (Pubitemid 40884229)
21. TY Kim KW Kim TS Jung JM Kim SW Kim KW Chung, et al. 2007 Prognostic factors for Korean patients with anaplastic thyroid carcinoma Head Neck 29 765 772 10.1002/hed.20578 17274052 (Pubitemid 47265532)
22. LA Pacheco-Ojeda AL Martínez M Alvarez 2001 Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors Int Surg 86 117 121 1:STN:280:DC%2BD387osF2isA%3D%3D 11918236
23. TV Bogsrud D Karantanis MA Nathan BP Mullan GA Wiseman JL Kasperbauer, et al. 2008 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma Thyroid 18 713 719 1:CAS:528:DC%2BD1cXos1ChsLs%3D 10.1089/thy.2007. 0350 18630999 (Pubitemid 352009926)
24. H Jadvar AJ Fischman 1999 Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography Clin Positron Imaging 2 153 158 10.1016/S1095-0397(99)00014-X 14516539
25. K Poppe T Lahoutte H Everaert A Bossuyt B Velkeniers 2004 The utility of multimodality imaging in anaplastic thyroid carcinoma Thyroid 14 981 982 10.1089/thy.2004.14.981 15671780
26. N Khan N Oriuchi T Higuchi K Endo 2005 Review of fluorine-18-2-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas Cancer Control 12 254 260 16258498
27. A Iagaru IR McDougall 2007 F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer Clin Nucl Med 32 13 15 10.1097/01.rlu.0000249591.51354.3e 17179796 (Pubitemid 46360586)
28. BD Nguyen PC Ram 2007 PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma Clin Nucl Med 32 145 149 10.1097/01.rlu.0000252240. 35579.2c 17242574 (Pubitemid 46148402)
29. RJ Robbins Q Wan RK Grewal R Reibke M Gonen HW Strauss, et al. 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning J Clin Endocrinol Metab 91 498 505 1:CAS:528:DC%2BD28XhsFKntb0%3D 10.1210/jc.2005-1534 16303836 (Pubitemid 43236915)
30. S Leboulleux PR Schroeder M Schlumberger PW Ladenson 2007 The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers Nat Clin Pract Endocrinol Metab 3 112 121 10.1038/ncpendmet0402 17237838 (Pubitemid 46146964)
31. S Leboulleux C Dromain G Bonniaud A Aupérin B Caillou J Lumbroso, et al. 2006 Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography J Clin Endocrinol Metab 91 920 925 1:CAS:528: DC%2BD28Xis1CmtL4%3D 10.1210/jc.2005-1540 16368753 (Pubitemid 43357759)
32. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782 1:STN:280: DC%2BD3c7jvV2ntA%3D%3D 10.1016/S0959-8049(99)00229-4 10673991 (Pubitemid 29512308)
33. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
34. NA Obuchowski 1998 On the comparison of correlated proportions for clustered data Stat Med 17 1495 1507 1:STN:280:DyaK1czmtVejtQ%3D%3D 10.1002/(SICI)1097-0258(19980715)17:13<1495::AID-SIM863>3.0.CO;2-I 9695194 (Pubitemid 28330346)
35. W Wang SM Larson M Fazzari SK Tickoo K Kolbert G Sgouros, et al. 2000 Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer J Clin Endocrinol Metab 85 1107 1113 1:CAS:528:DC%2BD3cXisFOru7Y%3D 10.1210/jc.85.3.1107 10720047 (Pubitemid 32269357)
36. M Rivera RA Ghossein H Schoder D Gomez SM Larson RM Tuttle 2008 Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma Cancer 113 48 56 10.1002/cncr.23515 18484584 (Pubitemid 351976385)
37. S Ben-Haim P Ell 2009 18F-FDG PET and PET/CT in the evaluation of cancer treatment response J Nucl Med 50 88 99 10.2967/jnumed.108.054205 19139187
38. L Decoster D Schallier H Everaert K Nieboer M Meysman B Neyns, et al. 2008 Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC) Lung Cancer 62 55 61 1:STN:280:DC%2BD1cnmtlKhtg%3D%3D 10.1016/j.lungcan.2008.02.015 18394750
39. CA Connell J Corry AD Milner A Hogg RJ Hicks D Rischin, et al. 2007 Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma Head Neck 29 986 995 10.1002/hed.20629 17563906
40. MK Kim JS Ryu SB Kim JH Ahn SY Kim SI Park, et al. 2007 Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy Eur J Cancer 43 1385 1391 10.1016/j.ejca.2007.04. 001 17512192 (Pubitemid 46874075)